Xolair omalizumab humanized monoclonal antibody against IgE regulatory update

The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 11-0 that Xolair has a favorable risk benefit ratio in

Read the full 182 word article

How to gain access

Continue reading with a
two-week free trial.